CASI Pharmaceuticals, Inc (DE)
CASIDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000895051
CASI Pharmaceuticals, Inc (DE) was delisted in 2023; its insiders filed their last Form 4 on Sep 9, 2022; 23 institutions reported holding it in 13F filings for Q4 2022, worth $3.31M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 23
- Q4 2022, −1 vs. previous quarter
- 13F value
- $3.31M
- Reported value at the end of Q4 2022
- Superinvestors holding
- 0
- At the end of Q4 2022
Superinvestors holding CASI, Q4 2022
No superinvestor reported holding CASI at the end of Q4 2022.
Latest insider trades
Open-market purchases and sales by CASI Pharmaceuticals, Inc (DE) insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2022 (view filing) | Sep 6-8 | 2 days | Huang JamesDirector | PPurchase | +55.6K | $4.13 | +$229.5K | +17.6%371.5K after | 3 lots |
| Sep 2, 2022 (view filing) | Aug 31-Sep 2 | 2 days | Huang JamesDirector | PPurchase | +37.2K | $3.74 | +$139.1K | +13.3%315.9K after | 3 lots |
| Aug 26, 2022 (view filing) | Aug 24-26 | 2 days | Huang JamesDirector | PPurchase | +44.5K | $3.75 | +$167.0K | +19.0%278.7K after | 2 lots |
| Aug 23, 2022 (view filing) | Aug 19-23 | 4 days | Huang JamesDirector | PPurchase | +234.2K | $3.33 | +$779.5K | New position234.2K after | 3 lots |
| Jun 17, 2022 (view filing) | Jun 13-15 | 4 daysLate | He Wei-WuChairman and CEO | PPurchase | +88.2K | $3.09 | +$272.5K | +15.8%644.6K after | 3 lots |
| Nov 19, 2021 (view filing) | Nov 17-18 | 2 days | He Wei-WuChairman and CEO | PPurchase | +400.0K | $0.985 | +$394.0K | +7.8%5.56M after | 2 lots |
| Aug 20, 2021 (view filing) | Aug 18-19 | 2 days | He Wei-WuChairman and CEO | PPurchase | +480.0K | $1.28 | +$613.8K | +10.2%5.16M after | 2 lots |
Top 10 13F holders, Q4 2022
The largest institutional positions in CASI Pharmaceuticals, Inc (DE) at the end of Q4 2022; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 900,651 | $1.58M | 0.00% | −114,349−11.3% | Reduced |
| Vanguard Group Inc | 257,618 | $461.1K | 0.00% | +175+0.1% | Added |
| Wellington Shields Capital Management, LLC | 206,148 | $369.0K | 0.04% | −12,099−5.5% | Reduced |
| Wellington Shields & Co., LLC | 145,315 | $260.1K | 0.06% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 98,133 | $171.0K | 0.00% | −175−0.2% | Reduced |
| BlackRock Inc. | 91,715 | $164.2K | 0.00% | +10.0% | Added |
| Susquehanna International Group, LLP | 57,395 | $100.4K | 0.00% | +23,758+70.6% | Added |
| State Street Corp | 35,555 | $62.2K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 25,593 | $45.8K | 0.00% | 00.0% | Unchanged |
| Franklin Resources Inc | 24,546 | $43.0K | 0.00% | 00.0% | Unchanged |